| Revista: | Brazilian Journal of Pharmaceutical Sciences |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000451864 |
| ISSN: | 1984-8250 |
| Autores: | Pontes, Marcela Amaral1 Robeiro, Alane Andrelino1 Rover, Marina Raijche Mattozo2 Leite, Silvana Nair2 |
| Instituciones: | 1Universidade de Brasilia, Faculdade de Ciencias da Saude,, Brasilia, Distrito Federal. Brasil 2Universidade Federal de Santa Catarina, Departamento de Ciencias Farmaceuticas, Florianopolis, Santa Catarina. Brasil |
| Año: | 2022 |
| Volumen: | 58 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | The COVID-19 pandemic puts the healthcare systems at risk due to the still uncertain operational and financial impacts of it. The difficult economic conditions of the population also call for more attention from government officials to define strategies that guarantee access to health services and products. Maintaining the supply chain of pharmaceutical products is not only paramount to cover the immediate medical response but will be fundamental to reducing disruption of the healthcare system. Increasing drug prices during the pandemic is definitely not a strategy that contributes to access. In this sense, this commentary presents a criticism of a decision by the Brazilian government that may impact the availability in health services and the population’s access to medicines necessary for the maintenance of life |
| Disciplinas: | Medicina |
| Palabras clave: | Salud pública, Farmacología, COVID-19, Pandemia, Precios, Medicamentos |
| Keyword: | Public health, Pharmacology, COVID-19, Pandemia, Prices, Drugs |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
